Recent studies have established that a complex community of microbes colonize the human urinary tract; however, their role in kidney transplant patients treated with prophylactic antibiotics remains poorly investigated. Our aim was to investigate the urinary microbiome of kidney transplant recipients. Urine samples from 21 patients after kidney transplantation and 8 healthy controls were collected. All patients received prophylactic treatment with the antibiotic combination trimethoprim-sulfamethoxazole. Metagenomic DNA was isolated from urine samples, sequenced using shotgun sequencing approach on Illumina HiSeq 2000 platform, and analyzed for microbial taxonomic and functional annotations. Our results demonstrate that the urine microbiome of kidney transplants was markedly different at all taxonomic levels from phyla to species, had decreased microbial diversity, and increased abundance of potentially pathogenic species compared with healthy controls. Specifically, at the phylum level, we detected a significant decrease in Actinobacteria and increase in Firmicutes due to increases in Enterococcus faecalis. In addition, there was an increase in the Proteobacteria due to increases in Escherichia coli. Analysis of predicted functions of the urinary metagenome revealed increased abundance of enzymes in the folate pathway including dihydrofolate synthase that are not inhibited by trimethoprim-sulfamethoxazole, but can augment folate metabolism. This report characterizes the urinary microbiome of kidney transplants using shotgun metagenomics approach. Our results indicate that the urinary microbiota may be modified in the context of prophylactic antibiotics, indicating that a therapeutic intervention may shift the urinary microbiota to select bacterial species with increased resistance to antibiotics. The evaluation and development of optimal prophylactic regimens that do not promote antibiotic resistance is an important future goal. (Translational Research 2017;181:59-70) Abbreviations: ESRD ¼ end-stage renal disease; UTI ¼ urinary tract infection
INTRODUCTION
Dysbiosis of the microbiome is associated with multiple diseases including obesity, pulmonary disease, inflammatory bowel disease, and colon cancer, among others. 1, 2 In parallel, numerous components of the microbiome also perform essential functions including production of cofactors and vitamins, metabolism of essential compounds, and barrier protection from pathogens. 3, 4 It is estimated that the human body harbors same order of bacteria compared to mammalian cells and such bacteria are likely essential for health. 5 The human gut microbiome is extensively investigated; importantly, there is emerging evidence that the urinary microbiome also has important biologic functions. Previous dogma suggested that urine was normally sterile in healthy subjects; however, recent studies have established that a complex microbial community containing hundreds of bacteria colonizes the healthy urinary tract. [6] [7] [8] A complex urinary microbiome has been documented by diverse collection methods including midstream clean-catch, transurethral catheters and percutaneous bladder puncture indicating that the urinary microbiome is not simply due to contamination or urethral colonization. 8, 9 Culture methods to diagnose clinical urinary tract infections (UTI) are designed to preferentially identify fast-growing bacterial species (eg, Escherichia coli and Enterococcus sp.), yet many fastidious species do not grow under typical laboratory conditions. Also, a clinical diagnosis of a UTI is based on a quantitative threshold (eg, . 10 4 CFU per mL) and excludes polymicrobial growth as contamination. 10 Thus, investigation of the roles of commensal vs pathogenic bacteria in the urinary microbiome requires improved methods such as the culture-and cloning-independent detection of microbiome by high-throughput shotgun metagenome sequencing, which is used in this study. Several previous microbiome studies sequenced only a portion of the 16S ribosomal RNA (rRNA) gene that is then used to predict the bacterial taxa. For example, the Human Microbiome Project focuses on the V1-V3 and V3-V5 region of the 16S rRNA gene to determine taxonomy. However, precise identification, particularly at the species and strain level, is challenging through this approach because of horizontal gene transfer among bacteria. Thus, shotgun metagenomics may provide increased power to investigate the microbiome. 11 An essential component of microbiome analysis is the emergence of databases of bacterial genes and genomes. Currently, greater than 6000 bacterial genomes have been sequenced and compiled in Genomes OnLine Database and Ensembl Bacteria, and greater than 9.3 million unique bacterial genes have been collated to date. 12, 13 Compared with the approximately 23,000 annotated genes in the human genome, the large number of bacterial genes illustrate the complex biological processes that can be contributed by the microbiome.
We investigated the urinary microbiome in kidney transplant patients. After transplantation, patients are exposed to prophylactic antibiotics and immunosuppressive agents which could modulate the microbiome and potentially result in dysbiosis. In this study, we used shotgun metagenomics to enhance the identification of bacterial genes and genomes in the urinary microbiome.
MATERIALS AND METHODS
Study design, patient cohort, and ethics statement. The objective of this study was to investigate the urinary microbiome in kidney transplant recipients and healthy controls using shotgun metagenomic sequencing. Urine samples were collected after transplant from 21 kidney AT A GLANCE COMMENTARY Rani A, et al.
Background
Recent studies have established the existence of a vivid ''microbiome'' comprising of hundreds of microbial species in healthy human urinary tract; however, it remains poorly investigated in kidney transplant recipients. We hypothesized that the microbiome may be altered in context to prophylactics regimen in kidney transplant recipients.
Translational Significance
We investigated the urinary microbiome of kidney transplant patients using shotgun metagenomics. Transplant group urinary microbiome was markedly different than healthy controls, with decreased bacterial species and diversity. Predicted functional analysis revealed that transplant group microbiome has the potential for increased production of genes in folate metabolic pathway which could reduce sensitivity to trimethoprim-sulfamethoxazole. Thus, our results demonstrate that the urinary microbiome is modified in the context of prophylactics and can alter the urinary microbiota to select bacterial species with increased resistance to antibiotics and enhanced pathogenicity. The evaluation and development of optimal prophylactic regimens that do not promote antibiotic resistance is an important future goal.
transplant recipients with known comorbidities and 8 control subjects. The controls included healthy adult subjects with no known comorbidities nor any history of UTI. Adult patients who received kidney transplants at the Washington University Medical Center, St. Louis, Mo., were included in the study. All patients were treated with a standard of care protocol. Patients received a total of 4 doses of rabbit antithymocyte globulin (Thymoglobulin [1.5 mg/kg each], Sang-Stat Medical Corp., Fremont, Calif.) for induction. The first dose was given intraoperatively followed by doses on postoperative days 1-3. Calcineurin inhibitors (CNI) were instituted on a brisk diuresis but no later than 4 days after operation. Target cyclosporine levels were 200-250 ng/mL during the first 3 months. Tacrolimus target levels were between 5 and 10 ng/mL. Maintenance immunosuppression included a CNI of either tacrolimus or cyclosporin, an antimetabolite and prednisone. Clinical information including laboratory results, infections, and medications were collected for each subject at the time of each clinic visit. Comorbidities including type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), hypertension (HTN), and ''other'' (which included focal segmental glomerulosclerosis, poststreptococcal glomerulonephritis, nephrocalcinosis, polycystic kidney disease, reflux nephritis, systemic lupus erythematosus, and vasculitis) were documented and listed in Table I . All patients received thymoglobulin for induction and a CNI inhibitor along with mycophenolate and prednisone for maintenance. Ureteral stents were removed at 1 month after transplantation. Samples were collected during the first 12 months after transplantation before the reported complications. The demographics of the transplant patients were 67% male, 33% female, 81% Caucasian, 19% African American, with an age range 31-76 years. The demographics of the control healthy subjects were 37.5% male, 62.5% female, 62.5% Caucasian, and 37.5% Asian, with an age range 27-63 years (Table I) . The control group did not have any pre-existing medical conditions such as kidney disease, UTI, and so forth. The control group did not consume any antibiotics (for at least 6 months) before participation in the study. Controls did not report any history of over-the-counter medications such as antipyretics or pain relievers. Informed consent was obtained from all subjects. Metagenome DNA isolation and sequencing. Urine obtained by midstream clean catch was processed in positive pressure airflow sterile hoods. One milliliter of urine from all samples was processed and was centrifuged at low speed at 180 3 g for 15 min at 4 C to remove the mammalian cells, and the supernatant was stored at 280 C until further processing. The urine samples were thawed and centrifuged at 100,000 3 g for 2 h at 4 C in an ultracentrifuge (Sorvall WX 80 Ultracentrifuge, Thermo Fisher Scientific Inc) to pellet down the microbial contents. The pellet was resuspended with 100 mL 1 3 PBS (Cellgro, Mediatech Inc) and subjected to DNaseI treatment (Invitrogen) for 15 min at 37 C, and the reaction was stopped by adding 2 mM EDTA and heating the content for 10 min at 65 C. The contents were subjected to enzymatic treatment by adding AL Buffer (DNAeasy kit; Qiagen), lysozyme (Fisher Bio Reagents), and enzyme solution (DNAeasy kit Handbook; Qiagen) for 2h at 37 C. Proteinease K was added to the mixture, and the DNA was eluted using the DNAeasy kit (Qiagen) protocol. The purified DNA was quantified using a Qubit fluorometer (Life Technologies Corporation), and equal amount of DNA from all samples were mechanically fragmented using a Covaris S220 (Covaris Inc). The DNA libraries for sequencing were prepared using the NEBNext DNA library prep kit for Illumina (New England BioLabs Inc). The quality and quantity of all the DNA libraries were analyzed with a Bioanalyzer 2100 (Agilent Technologies) and Qubit fluorometer. Equal amount of all the DNA libraries were sequenced on an Illumina HiSeq 2000 generating 50 base single-end reads (BGI Americas). Control libraries were prepared by using 1 3 PBS buffer instead of urine and were subjected to the same DNA isolation protocol as for test urine samples. As expected, there was no detectable DNA by Qubit analysis. The control DNA was then used to prepare metagenome libraries, and no libraries were detected by Bioanalyzer analysis and thus not quantifiable. The control libraries were pooled and sequenced with the test libraries. After demultiplexing of the sequence reads, no reads were assigned to the control libraries.
Bioinformatics analyses and taxonomic and metabolic annotations. Raw DNA sequence reads were quality trimmed and filtered to remove human DNA sequences by mapping against the human reference genome using standard default parameters (CLC Genomics Workbench; CLC Bio, Aarhus, Denmark). Filtered (nonhuman) sequences were assembled into contigs using the minimum contig length of 300 bp for each sample. Taxonomic and functional annotations of the contigs were obtained using the automated annotation pipeline at MG-RAST web server Demographic data including sample number, gender, age, ethnicity, ESRD cause, calcineurin inhibitor, and use of ureteral stent for anastomosis (stents were removed at 1 mo after transplant). Abbreviations: CYA, cyclosporine A; FK, Tacrolimus (FK-506); FSGS, focal segmental glomerulosclerosis; HTN, hypertension; NA, not available; PKD, polycystic kidney disease; PSGN, poststreptococcal glomerulonephritis; RN, reflux nephropathy; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus. All rejection episodes were treated with steroids. *Bacterial infections were reported post sample collection and from 3 to 6 mo after transplant. † Grouped as ''other'' category for analysis.
(http://metagenomics.anl.gov/) using the maximum e-value 1e 25 cutoff, and minimum 80% identity cutoff using M5NR and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases, respectively.
14 The contigs were assigned to KEGG Orthology (KO) gene identifiers and frequencies in the transplant, and control groups were determined. 15 The KOs were constructed into metabolic pathways and biological processes using a KEGG mapper. Each sample was compared at the phylum, genus, and species levels; at the KEGG pathway levels I, II, and III; and at the functional level. 15 Taxa at the species level with $1% of the reads were defined as abundant. Relative abundance for each taxon and metabolic feature was normalized by the percentages of total assigned reads of the metagenome.
Statistical analyses. Data corresponding to both functional and taxonomical distributions were analyzed as described. 16 Differences between 2 groups were assessed using the Mann-Whitney U test. Data sets that involved more than 2 groups were assessed by analysis of variance followed by Tukey's multiple comparison post hoc tests. Data were analyzed using GraphPad Prism (GraphPad Software, San Diego, Calif.). Data were considered as statistically significant with P , 0.05 unless otherwise indicated. Wilcoxon rank-sum test was used for comparison between the 2 groups, with P value of ,0.05 considered as a significant difference after multiple test corrections with Benjamini-Hochberg false discovery rate (FDR). Principal Coordinate Analysis (PCoA) was performed to find the axis that best explains the variance in the data set. The PCoA plot was generated using the Bray-Curtis dissimilarity matrix for phylum and species between the transplant and control groups. Microbiome profile at species level was also analyzed by partial least squares discriminant analysis. 17 Cluster analysis was performed using the Pearson correlation distance with Ward method between the transplant and control groups at phylum and species level, as described. 17 To test for significant differences in the transplant and control group, a 1-way analysis of similarity (ANOSIM) was conducted as described. 18 High-throughput sequencing data availability. The sequence data have been submitted to the MG-RAST web server under the following accession numbers: 4504962. 3 Table S1 . A PCoA identified distinct clusters of the transplant and control groups at both the phylum and species levels (Fig 1) . The first principal component contributed 25.5% and 17.7% to the variance of the phyla and species, respectively (Fig 1) . We also determined the separation of the transplant and control microbiomes by Ward's hierarchical clustering method using the Pearson correlation similarity measure ( Figure S1 ). The dendrogram confirmed segregation of the transplant and control microbiomes similar to the PCoA analysis. To determine the effects of kidney transplantation on the urinary microbiome, we analyzed the microbial taxa in the urine of kidney transplant recipients and healthy controls (Table II) . These analyses indicate that the transplant and control groups have markedly different microbial compositions. Partial least squares discriminant analysis was performed on all samples with grouping according to transplant and control statuses. This analysis revealed 2 separate microbiome profiles in the transplant and control groups ( Figure S2a ). The pairwise 1-way ANOSIM test showed that the transplant and control groups differ significantly (1-way ANOSIM, Global R 5 0.37, P , 0.001, number of permutations 5 9999) and within-group variability was low compared to between-group variability ( Figure S2b) .
Analysis of the microbial taxa. We analyzed the microbiome profile in transplant and control samples, and the major phyla are shown in Figure S3a . The urinary microbiome of the transplant group is dominated by 2 major bacterial phyla, Firmicutes and Proteobacteria, whereas the control group is dominated by Actinobacteria and Proteobacteria (Table II) . Other minor phyla detected were Bacteroidetes and ''other phyla'' which included 23 low-abundant phyla (each detected with an abundance ,2%). We detected major alterations in the proportions of 2 phyla revealing an expansion of Firmicutes from 11.6% to 39.5% (P , 0.05) and a reduction of Actinobacteria from 41.0% to 6.4% (P , 0.005) in the transplant group compared with controls. A small increase in the phylum Proteobacteria and decrease in Bacteroidetes were observed in the transplant group; however, these trends did not reach statistical significance. To focus on a more specific level of classification, we next analyzed the data at the species level which is feasible with the application of shotgun metagenomics (Table III) . First, we observed that only 8 species (among the top 21 species identified as abundant species in both groups) were shared between the groups, whereas 13 species were specific to a single group. We observed a significant increase in the transplant group in multiple species including Enterococcus faecalis, E. faecium, Enterococcus sp., E. coli, and Escherichia sp., compared with low levels of these species in the control group (P , 0.05). In contrast, there was a significantly higher abundance of the species Propionibacterium acnes (17.8%) in the control group (P , 0.05). The abundance of E. faecalis, E. coli, and P. acnes in the transplant and control samples are given in Figures S3b-d . The species Corynebacterium amycolatum, Neisseria meningitidis, and Mobiluncus curtisii were high in abundance (more than 1%) in the control group, although none of these species were detected in high abundance in the transplant group (Table III) .
We also compared the microbiomes at the genus level which was consistent with our analyses of the phyla and species. For example, the increase in the phylum Firmicutes in the transplant group was to a large extent due to an increase in the genus Enterococcus which includes 4 Enterococcus species (Table S2 ). The increase in the phylum Actinobacteria in the control group corresponded with an enrichment of the genera Propionibacterium, Corynebacterium, and Mobiluncus which includes a large increase in the species Propionibacterium acnes, a smaller increase in Mobiluncus curtisii, and increases in 4 species of Corynebacterium. Thus, the changes observed in phyla, genera, and species were internally consistent with bacterial taxonomy, but the analysis at the species level provided the most detailed discrimination. There was no significant correlation with the time after transplantation and the abundance of the major bacterial phyla-Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria ( Figure S7 ).
Decreased bacterial diversity of the urinary microbiome of transplant patients. Overall, the urinary microbiome of the transplant group included a total of 1210 species, whereas a total of 1420 species were identified in the control group (Fig 2) . Both groups shared 1016 (62.9%) bacterial species, but with variable relative abundance. The number of species unique to the transplant (194) and control group (404) revealed that The difference between the relative abundance of individual phylum in the transplant and control microbiomes was computed using a Wilcoxon rank-sum test *P , 0.05, **P , 0.005, (FDR corrected). Other phyla included 23 different phyla with an abundance ,2%.
only 12% and 25% of the species were unique to transplant and control groups, respectively. To assess the ecological structure of the urinary microbiomes, we estimated the diversity and evenness of the bacterial populations. The Shannon diversity index for the transplant group (2.8 6 0.2) was significantly lower than the control group (4.8 6 0.2, P , 0.0001; Fig 3, A, Table S3 ). The inverse Simpson index was also significantly lower in the transplant group (Table S3) . However, species evenness values were similar in both the groups (Fig 3, B , Table S3 ). These results indicated a significant decrease in community diversity in the transplant group as measured by both the Shannon and Simpson indices.
No effect of different primary diagnoses of end-stage renal disease on microbial composition. The transplant patient population in our study includes several diagnoses, categorized into 4 subgroups including T1DM, T2DM, HTN, and other. We further investigated whether the differences in the composition of the urinary microbiome were associated with specific diagnoses. An analysis of variance comparison of the proportion of bacterial phyla and species in the 4 clinical diagnoses revealed no significant differences in the microbial composition among the 4 clinical diagnoses (Tables S4 and S5 ). However, similar to results for the whole transplant group, these categories were significantly different at the phylum and species levels compared with the control group ( Figure S4a) . Also, the Shannon diversity index calculated for the 4 subgroups of clinical diagnosis showed no significant difference among clinical diagnoses; however, they were significantly different from controls ( Figure S4b and Table S5 ). These data suggest that there may be no effect of different primary diagnoses of end-stage renal disease (ESRD) on microbial composition. Bacterial species identified in transplant and control groups (selected on the basis of .1% abundance in transplant group). Species identified in both the groups are shown in bold letters, whereas nonbold letters are the species specific to each group. Statistical significance was determined by Wilcoxon rank-sum test. *P , 0.05. Analysis of folate metabolic pathway. To determine if the metabolic potential of the urinary microbiome was different in the transplant and control groups, we analyzed the bacterial metagenomes in each group for biological functions with the KEGG catalog and assigned KEGG identifiers for predicted genes. Our analysis of the level 1 KEGG categories, which include the most general functional classifications, showed a major contribution of metabolism (58%-61%) to the overall KEGG processes; however, there were no significant differences between the transplant and control groups ( Figure S5 and Table S6 ). In contrast, analysis at the more specific level 4 (functional level) showed a significant difference in folate metabolism. Thus, the transplant and control groups had similar general metabolic processes (level 1) but exhibited distinct differences in the more specific enzymes in the pathways (level 4). Of note, we observe an increase in enzymes in the folate pathway by the transplant microbiome (Fig 4) including increases in dihydrofolate synthase or folypolyglutamate synthase (Fig 5) . We compared the abundance of genes (at functional level) involved in the folate metabolism pathway in the 3 major phyla-Firmicutes, Proteobacteria, and Actinobacteria in transplant and control groups. These phyla were the major contributors to the changes in the bacterial diversity after transplantation. At phylum level, Firmicutes and Proteobacteria in transplant group and Proteobacteria and Actinobacteria in control group were enriched for folate biosynthesis genes ( Figure S6a) . However, no predicated folate functions were detected in Actinobacteria and Firmicutes, of transplant and control group, respectively. We further compared these changes in the bacterial species which were highly abundant in each group; E. faecalis (PhylumFirmicutes) and E. coli (Phylum-Proteobacteria) in transplant group, whereas in control group, P. acnes (Phylum-Actinobacteria) was enriched for folate biosynthesis genes ( Figure S6b ).
DISCUSSION
Our study identified major changes in the urinary microbiome after kidney transplantation. These changes were detected in the all of the major taxa including phyla, genera, and species based on both PCoAs, hierarchical clustering and multivariate analysis (Fig 1, S1 and S2). The richness and a-diversity of the bacterial species detected in the transplant and control urines were significant between the groups (Fig 3, Table S3) . At the phyla level, the transplant group had a significant decrease in Actinobacteria and increase in Firmicutes, whereas the other major phyla including Proteobacteria and Bacteroidetes did not show significant changes (Table II) . At the species level, the transplant group had significant increases in E. coli and E. faecalis, 2 potentially pathogenic species, and decreases in P. acnes, a nonpathogenic species (Table III) . The ecological structure of the microbiomes was also significantly different. Both the Shannon and Simpson indices (Table S3) showed significantly lower diversity in the transplant microbiome which is consistent with the observations that diversity is often lower in a disease state than in health. 19 Thus by inference, the kidney transplant urine microbiome is more susceptible to dysbiosis. In addition, we show that the complexity of the microbiome in the transplant population is significantly lower than that of healthy controls which is suggestive of a less-stable bacterial community.
In an analysis of predicted functions, the transplant microbiome has increased abundance of genes that produce enzymes in the folate metabolic pathway (Figs 4 and 5) . Interestingly, the increased genes are not direct targets of the antibiotic which could reduce sensitivity to trimethoprim-sulfamethoxazole, a commonly administered antibiotic that is used as a prophylactic treatment in transplant patients. The taxonomic analysis establishes several important observations. First, the urine of the healthy nontransplant controls contained a diverse microbiome consisting of 10 different abundant bacterial species (.1%), plus .990 nonabundant (,1%) species. Thus, the urine was not sterile in either the healthy controls or the transplant patients but colonized with a complex community of bacteria. We underscore that the clinical diagnosis of a UTI depends on growth of greater than a defined threshold number of colonies (eg, .10 5 CFU per mL), whereas the significance of the presence of a smaller colony number is not clear. Our method of using cloning-and culture-independent, high-throughput DNA sequencing of bacterial DNA is exquisitely sensitive and advantageous to investigate the microbiome because there are no known laboratory techniques to culture .90% of bacterial species. 20 It is possible that some or all of the abundant colonizing bacteria in the healthy controls are beneficial and perhaps prevent the invasion of pathogenic species. After transplantation, patients are exposed to multiple stressors including treatment with prophylactic antibiotics and immunosuppressive drugs. Our data suggest that these stressors precipitate changes in the urinary microbiome including the expansion of potentially pathogenic bacterial species. This is consistent with a previous report showing a greater change in the urinary microbiome between 0 and 1 month than between 1 and 6 months after transplantation. 21 Of note, of the 21 urine samples, 11 samples had high abundance of E. faecalis, defined as greater than 10% relative abundance, established through metagenome sequencing and E. faecalis UTI developed within this group. A total number of patients with culture-positive UTI is 4 (Table IV) , with E. faecalis abundance of .10% and with elevated dihydrofolate synthetase gene. Interestingly, Enterococcus is also abundant in the transplant recipients without a UTI, and it was also detected in control samples, although at lower abundance. These results suggest that the bacterial species causing a clinical UTI may be members of the colonizing microbiome present before the development of a clinical infection. This interpretation suggests that clinical UTIs may not be only due to the invasion of a pathogenic strain that ascends the urinary tract or traverses from the blood, but also due to the emergence of a pathogenic strain after a perturbation that disrupts the homeostasis that was maintaining the microbial community. Therapeutic or probiotic modification of the colonizing microbiome may be effective in ameliorating the severity and frequency of clinical UTIs and urosepsis.
Because our transplant patient population had multiple primary diagnoses associated with the development of end-stage renal disease including T1DM, T2DM, HTN, and ''other,'' we evaluated the possibility that changes in the transplant urinary microbiome were due to these primary diagnoses. Our results suggest that there were no significant differences in the taxa among the 4 diagnoses; however, as expected, each diagnosis was significantly different from the healthy controls. Similar results were observed in the analysis of diversity with no differences observed among the 4 diagnoses, but again each diagnosis showed significantly decreased diversity compared with the healthy controls. Thus, metabolic effects due to diabetes mellitus (DM) or other primary diseases were not the source of the changes in the microbiome after transplantation ( Figure S4 ). A similar profile of bacterial diversity including Corynebacterium, Staphylococcus, Streptococcus, Propionibacterium, and Ralstonia has been reported previously. 6, 22, 23 A recent study by Fricke et al, 21 using 16S rRNA amplicon sequencing also analyzed the microbiome in renal transplant patients, and, similar to our results, detected increasing abundance of Firmicutes with time after transplantation. However, their study detected ,350 operational taxonomic units per sample, whereas our data detected 1210 total species. The difference is likely due to the technical difference between the targeted 16S rRNA amplicon and shotgun metagenomics sequencing that detected an average of 4652 vs 140,918 sequence reads per sample, respectively. In addition, the study by Fricke et al, detected bacteria in 33% of the urine samples, whereas our data detected bacteria in 100% of the samples. Importantly, the increased sequencing depth and shotgun approach facilitated our analysis of KEGG pathways at the species level. The overall observations in our study are enhanced by the use of shotgun metagenomics which permits more precise identification of the bacterial genes and genomes in the sample than 16S rRNA based methods, which rely on sequencing a fragment of the 16S rRNA gene and then predicting the associated taxa. More accurate identification of the bacterial genomes strengthens both the classification of the species and the predictions of putative biologic functions. 11 For example, our analysis predicts increased folate production by the transplant microbiome. After transplantation, the standard of care treatment includes prophylactic trimethoprim-sulfamethoxazole, which inhibits 2 enzymes in the folate metabolic pathway, to prevent UTI. The extensive use of this antibiotic has led to widespread resistance in up to 25% of some bacterial species. The resistance has been shown to occur by a number of different mechanisms including synthesis of drug-resistant plasmid-encoded dihydrofolate synthetase, hyperproduction of para-aminobenzoic acid, or metabolic alteration of the drug entity. 24, 25 Our data show that opportunistic pathogenic bacterial species (eg, E. faecalis and E. coli) may develop mechanisms to resist the prophylactic antibiotics in the transplant group.
Our study did not detect significant changes in the levels of genes for both dihydropteroate synthase and dihydrofolate reductase in the transplant, which are targets of trimethoprim-sulfamethoxazole. However, dihydrofolate synthase or folylpolyglutamate synthase, which has the potential to promote folate production from tetrahydrofolate-polyglutamate by enzymes not directly inhibited by trimethoprim-sulfamethoxazole, is produced in the transplant group. Thus, the microbiome in the transplant group has the potential to express metabolic pathways that could bypass the inhibition by trimethoprim-sulfamethoxazole. These results suggest that prophylactic antibiotic treatment could alter the urinary microbiome after transplantation to select bacterial species with resistance to antibiotics. Because the observed shift in the microbiome following transplantation is toward potentially pathogenic bacterial species, it will be important in future studies to confirm the changes in folate metabolism with metatranscriptomics and to evaluate optimal prophylactic regimens.
